The Testing Evidence for Using Ivermectin for Treating Brain Cancer

Executive Summary

  • Ivermectin is proven to treat a variety of different cancers.
  • Brain cancer is one of them.


In a previous article titled How Ivermectin Is Useful for Treating Cancer we covered the evidence for the benefits of Ivermectin for cancer. But the question of which cancers Ivermectin has been proven to be effective is a constant source of questions.

This article provides an overview coverage of these specific cancers.

There are a lot of quotes in this article, but I have a short one for each cancer type. The article uses the term “IVM” to mean Ivermectin

Cancer Type #8:Brain Cancer

These results showed that IVM had the potential to resist tumor angiogenesis and tumor metastasis. However, here, we must emphasize that because IVM cannot effectively pass the blood-brain barrier, the prospect of the use of IVM in the treatment of gliomas is not optimistic.

Glioma is the most common cerebral tumor and approximately 100,000 people worldwide are diagnosed with glioma every year. Glioblastoma is the deadliest glioma, with a median survival time of only 14-17 months [61,62]. Experiments showed that IVM inhibited the proliferation of human glioblastoma U87 and T98 G cells in a dose-dependent manner and induced apoptosis in a caspase-dependent manner [63]. This was related to the induction of mitochondrial dysfunction and oxidative stress. Moreover, IVM could induce apoptosis of human brain microvascular endothelial cells and significantly inhibit angiogenesis. These results showed that IVM had the potential to resist tumor angiogenesis and tumor metastasis. In another study, IVM inhibited the proliferation of U251 and C6 glioma cells by inhibiting the Akt/mTOR pathway [64]. – NIH

The Importance of The NIH Stopping Any Funding For Ivermectin Studies

Notice that none of the studies on Ivermectin were performed in the US. The US has by far the largest national medical research budget in the world, and so if the US is not performing studies, this is not only a negative but tells us something peculiar about what the NIH is deciding not to fund in the area of cancer research.

Zero is the number of studies funded by the NIH on Ivermectin. The NIH will not fund studies into generic drugs, as the NIH is controlled by pharmaceutical companies and they have deep financial ties to them. Funding research into generic drugs could end up showing those drugs as effective, which is a threat to pharmaceutical profits, which the NIH is dedicated to maximizing.